Evidence map›Paper›PMID 33852918›Full record

ArticleChest2021

Breast and Lung Effusion Survival Score Models: Improving Survival Prediction in Patients With Malignant Pleural Effusion and Metastasis.

Sofia Molina, Gabriela Martinez-Zayas, Paula V Sainz, Cheuk H Leung, Liang Li, Horiana B Grosu, Roberto Adachi, David E Ost

Open access · greenAbstract read
In one paragraph

Article in Chest, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Sofia MolinaDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Gabriela Martinez-ZayasDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Paula V SainzDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; School of Medicine and Health Sciences, Tecnologico de Monterrey, Monterrey, Mexico.
Cheuk H LeungDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Liang LiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Horiana B GrosuDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Roberto AdachiDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
David E OstDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: dost@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USTecnológico de Monterrey · MX

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundEvidence-based guidelines recommend management strategies for malignant pleural effusions (MPEs) based on life expectancy. Existent risk-prediction rules do not provide precise individualized survival estimates. RESEARCH QUESTION: Can a newly developed continuous risk-prediction survival model for patients with MPE and known metastatic disease provide precise survival estimates? STUDY DESIGN AND

methodsSingle-center retrospective cohort study of patients with proven malignancy, pleural effusion, and known metastatic disease undergoing thoracentesis from 2014 through 2017. The outcome was time from thoracentesis to death. Risk factors were identified using Cox proportional hazards models. Effect-measure modification (EMM) was tested using the Mantel-Cox test and was addressed by using disease-specific models (DSMs) or interaction terms. Three DSMs and a combined model using interactions were generated. Discrimination was evaluated using Harrell's C-statistic. Calibration was assessed by observed-minus-predicted probability graphs at specific time points. Models were validated using patients treated from 2010 through 2013. Using LENT (pleural fluid lactate dehydrogenase, Eastern Cooperative Oncology Group performance score, neutrophil-to-lymphocyte ratio and tumor type) variables, we generated both discrete (LENT-D) and continuous (LENT-C) models, assessing discrete vs continuous predictors' performances.

resultsThe development and validation cohort included 562 and 727 patients, respectively. The Mantel-Cox test demonstrated interactions between cancer type and neutrophil to lymphocyte ratio (P < .0001), pleural fluid lactate dehydrogenase (P = .029), and bilateral effusion (P = .002). DSMs for lung, breast, and hematologic malignancies showed C-statistics of 0.72, 0.72, and 0.62, respectively; the combined model's C-statistics was 0.67. LENT-D (C-statistic, 0.60) and LENT-C (C-statistic, 0.65) models underperformed.

interpretationEMM is present between cancer type and other predictors; thus, DSMs outperformed the models that failed to account for this. Discrete risk-prediction models lacked enough precision to be useful for individual-level predictions.

Indexed as

Clinical Decision RulesNeoplasmsPatient SelectionPleural Effusion, MalignantProportional Hazards ModelsThoracentesisAnalysis of VarianceFemaleHumansLife TablesL-Lactate DehydrogenaseLymphocyte CountMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingL-Lactate Dehydrogenasemalignant pleural effusionsprediction modelsurvival analysis

Identifiers

PMID33852918
PMCPMC8449006
OpenAlexW3154972927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.